SEARCH OUR PAGES

Vaccine Platform

Vaccine Platform

OSE Immunotherapeutics leverages its expertise in the selection and optimization of small proteins called peptides (epitopes or neo-epitopes) to deliver a rationally designed combination of multiple peptides with beneficial therapeutic potential.

The Company uses knowledge and expertise generated from its Memopi ® epitope (neo-epitope) optimization technology a combination of antitumor neo-epitopes to increase the memory immune response of T lymphocytes against specific antigens.

This expertise and technology were recently successfully validated in the Step 1 of the Phase 3 clinical testing for Tedopi® in non-small cell lung cancer and provide the basis for the development program of CoVepiT, a COVID-19 vaccine.

Platform
Target/Modality
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Partners
Tedopi®
Neoepitopes
NSCLC post ICI failure
Positive Step-1 results : Survival and safety
Tedopi®
Neoepitopes
Advanced pancreatic cancer
Combo with PD1 Opdivo® ongoing
CoVepiT
Optimized Neoepitopes of SARS-CoV-2
COVID-19 vaccine
Positive preclinical results (August 2020)
Expected Q1 2021

Platform

  • Target Modality Neoepitopes
  • Indication NSCLC post ICI failure
  • Pre-Clinical POC
  • Phase 1
  • Phase 2
  • Phase 3 Positive Step-1 results : Survival and safety
  • Partners
  • Target Modality Neoepitopes
  • Indication Advanced pancreatic cancer
  • Pre-Clinical POC
  • Phase 1
  • Phase 2 Combo with PD1 Opdivo® ongoing
  • Phase 3
  • Partners
  • Target Modality Optimized Neoepitopes of SARS-CoV-2
  • Indication COVID-19 vaccine
  • Pre-Clinical POC Positive preclinical results (August 2020)
  • Phase 1 Expected Q1 2021
  • Phase 2
  • Phase 3
  • Partners
  • CoVepiT

    +
  • Tedopi®

    +